Oral antiplatelet therapy for acute coronary syndromes: Aspirin, P2Y12 inhibition and thrombin receptor antagonists

Alison L. Bailey, Charles Campbell

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The platelet is central to the pathophysiology of acute coronary syndromes (ACS) via its direct participation in the formation of the thrombotic occlusion and its participation in the coagulation cascade that results in the formation of thrombin. Antiplatelet therapy is a cornerstone of therapy in the setting of ACS. Unfortunately, many patients who receive intensive antiplatelet therapy remain at high risk for recurrent events. Current efforts to reduce this "residual risk" include lifestyle modifications, cardiac rehabilitation, and intensive therapy for dyslipidemia. Also being investigated are methods of individualizing and intensifying antiplatelet therapy. Novel compounds that promise to reduce recurrent ischemic events without an increase in bleeding events are being evaluated in clinical trials. This review summarizes ongoing efforts to improve the effectiveness of antiplatelet therapy among patients with ACS.

Original languageEnglish (US)
Pages (from-to)1805-1812
Number of pages8
JournalCurrent Drug Targets
Volume12
Issue number12
DOIs
StatePublished - Nov 1 2011

Fingerprint

Thrombin Receptors
Acute Coronary Syndrome
Aspirin
Platelets
Coagulation
Thrombin
Patient rehabilitation
Therapeutics
Dyslipidemias
Inhibition (Psychology)
Life Style
Blood Platelets
Clinical Trials
Hemorrhage

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Oral antiplatelet therapy for acute coronary syndromes : Aspirin, P2Y12 inhibition and thrombin receptor antagonists. / Bailey, Alison L.; Campbell, Charles.

In: Current Drug Targets, Vol. 12, No. 12, 01.11.2011, p. 1805-1812.

Research output: Contribution to journalReview article

@article{9daa254ff7a5456f8b59de6aaddd989e,
title = "Oral antiplatelet therapy for acute coronary syndromes: Aspirin, P2Y12 inhibition and thrombin receptor antagonists",
abstract = "The platelet is central to the pathophysiology of acute coronary syndromes (ACS) via its direct participation in the formation of the thrombotic occlusion and its participation in the coagulation cascade that results in the formation of thrombin. Antiplatelet therapy is a cornerstone of therapy in the setting of ACS. Unfortunately, many patients who receive intensive antiplatelet therapy remain at high risk for recurrent events. Current efforts to reduce this {"}residual risk{"} include lifestyle modifications, cardiac rehabilitation, and intensive therapy for dyslipidemia. Also being investigated are methods of individualizing and intensifying antiplatelet therapy. Novel compounds that promise to reduce recurrent ischemic events without an increase in bleeding events are being evaluated in clinical trials. This review summarizes ongoing efforts to improve the effectiveness of antiplatelet therapy among patients with ACS.",
author = "Bailey, {Alison L.} and Charles Campbell",
year = "2011",
month = "11",
day = "1",
doi = "10.2174/138945011797635830",
language = "English (US)",
volume = "12",
pages = "1805--1812",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "12",

}

TY - JOUR

T1 - Oral antiplatelet therapy for acute coronary syndromes

T2 - Aspirin, P2Y12 inhibition and thrombin receptor antagonists

AU - Bailey, Alison L.

AU - Campbell, Charles

PY - 2011/11/1

Y1 - 2011/11/1

N2 - The platelet is central to the pathophysiology of acute coronary syndromes (ACS) via its direct participation in the formation of the thrombotic occlusion and its participation in the coagulation cascade that results in the formation of thrombin. Antiplatelet therapy is a cornerstone of therapy in the setting of ACS. Unfortunately, many patients who receive intensive antiplatelet therapy remain at high risk for recurrent events. Current efforts to reduce this "residual risk" include lifestyle modifications, cardiac rehabilitation, and intensive therapy for dyslipidemia. Also being investigated are methods of individualizing and intensifying antiplatelet therapy. Novel compounds that promise to reduce recurrent ischemic events without an increase in bleeding events are being evaluated in clinical trials. This review summarizes ongoing efforts to improve the effectiveness of antiplatelet therapy among patients with ACS.

AB - The platelet is central to the pathophysiology of acute coronary syndromes (ACS) via its direct participation in the formation of the thrombotic occlusion and its participation in the coagulation cascade that results in the formation of thrombin. Antiplatelet therapy is a cornerstone of therapy in the setting of ACS. Unfortunately, many patients who receive intensive antiplatelet therapy remain at high risk for recurrent events. Current efforts to reduce this "residual risk" include lifestyle modifications, cardiac rehabilitation, and intensive therapy for dyslipidemia. Also being investigated are methods of individualizing and intensifying antiplatelet therapy. Novel compounds that promise to reduce recurrent ischemic events without an increase in bleeding events are being evaluated in clinical trials. This review summarizes ongoing efforts to improve the effectiveness of antiplatelet therapy among patients with ACS.

UR - http://www.scopus.com/inward/record.url?scp=80054055635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054055635&partnerID=8YFLogxK

U2 - 10.2174/138945011797635830

DO - 10.2174/138945011797635830

M3 - Review article

C2 - 21718239

AN - SCOPUS:80054055635

VL - 12

SP - 1805

EP - 1812

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 12

ER -